Oral GLP-1 Pills vs Compounded Tirzepatide: A 2026 Comparison
Released: Last reviewed:
For the first time, there is an FDA-approved GLP-1 weight-loss pill. Here is how it compares to compounded tirzepatide on results, convenience, cost, and FDA status — and how to think about the choice with a clinician.
Direct answer
As of July 2026, the newest option is Foundayo (orforglipron), the first small-molecule GLP-1 pill for chronic weight management, FDA-approved on April 1, 2026. It is a once-daily tablet that produced roughly 11–12% average body-weight loss at 72 weeks on its highest dose in the ATTAIN-1 trial. Compounded tirzepatide is a weekly injection, is not FDA-approved, and uses a different molecule (a dual GIP/GLP-1 agonist); injectable tirzepatide averaged about 15–21% by dose in SURMOUNT-1. The short version: the pill trades some average efficacy for needle-free convenience and FDA approval. Which fits you is a clinical decision, not a foregone conclusion.
What changed in 2026
On April 1, 2026, the FDA approved Foundayo (orforglipron) from Eli Lilly for adults with obesity, or overweight with a weight-related condition, alongside diet and activity. It is notable for two reasons: it is a pill rather than an injection, and unlike the earlier oral GLP-1 Rybelsus (semaglutide, approved only for type 2 diabetes), it can be taken any time of day with or without food or water. Major telehealth platforms moved quickly — Ro signed a deal with Lilly in April 2026 to offer it — so patients are increasingly seeing a pill option next to the injectables. Details are tracked on our FDA news page.
How they differ at a glance
| Foundayo (orforglipron) pill | Compounded tirzepatide | |
|---|---|---|
| Type | Once-daily oral tablet | Weekly injection (self-administered) |
| Molecule | Single GLP-1 agonist (non-peptide) | Dual GIP/GLP-1 agonist (peptide) |
| FDA status | FDA-approved (April 1, 2026) | Not FDA-approved |
| Average weight loss | ~11–12% at 72 wks (highest dose, ATTAIN-1) | Injectable tirzepatide ~15–21% by dose (SURMOUNT-1) |
| Typical cost | $25/mo with commercial coverage; $149 self-pay via LillyDirect | Varies by provider and pharmacy pathway; verify directly |
| Needles | None | Yes (weekly) |
Figures are approximate and drawn from manufacturer and trial reporting; exact numbers vary by analysis and dose. Verify current pricing and eligibility directly. Weight-loss figures compare different molecules and trials and are not head-to-head.
Weight-loss results: what the trials show
In the ATTAIN-1 program, adults on the highest orforglipron dose lost on the order of 11–12% of their body weight on average at 72 weeks (about 27 pounds among those who stayed on treatment), versus roughly 2% on placebo, with improvements in cardiometabolic markers. Injectable tirzepatide, in the SURMOUNT-1 trial, produced about 15% at the lowest dose up to roughly 21% at the highest over a comparable window. These are different trials and different molecules, so treat the comparison as directional rather than head-to-head, but the pattern — greater average loss from injectable tirzepatide — is consistent with how a dual agonist tends to perform.
Convenience, needles, and daily vs weekly
For people who dislike or fear needles, a daily pill is a meaningful difference. The tradeoff is a daily habit rather than a weekly one, and — as with any GLP-1 — gastrointestinal side effects such as nausea are common, especially during dose escalation. Neither route is “easier” in absolute terms; it depends on whether a weekly injection or a daily tablet fits your life better.
Cost and access
Foundayo is available through LillyDirect with pricing advertised at about $25/month with commercial coverage and $149/month for self-pay, and is expanding into retail and telehealth channels. Compounded tirzepatide pricing varies widely by provider and pharmacy pathway, and — as covered in our price comparison — advertised teaser prices often differ from the true monthly cost. Because brand-name tirzepatide is also more available than during the shortage, it is worth pricing all three routes for your situation rather than assuming compounded is automatically cheapest.
FDA approval vs compounded status
This is the cleanest distinction. Foundayo is FDA-approved, meaning it was reviewed for safety, effectiveness, quality, and labeling. Compounded tirzepatide is not — regardless of how reputable the pharmacy is — and its availability now depends on patient-specific 503A compounding with a documented clinical need. If FDA approval is a priority for you, that alone may point toward the pill or brand injectable. See our legal status and safety explainers for the fuller picture.
Who each option might suit
Broadly, and only as a starting point for a conversation with a clinician: a pill may appeal to people who want an FDA-approved, needle-free option and are comfortable with somewhat lower average weight loss; injectable tirzepatide may suit those prioritizing the largest average results and who tolerate a weekly injection. Compounded tirzepatide sits in a narrower lane now — it is not FDA-approved and depends on a documented clinical need — so anyone considering it should weigh that against the newly available approved alternatives.
Recent changes
July 9, 2026: Published; approval date, trial figures, and pricing verified against manufacturer and trial reporting.
April 1, 2026: FDA approved Foundayo (orforglipron), the first oral GLP-1 pill for weight management.
Key takeaways
There is now an FDA-approved GLP-1 pill, Foundayo (orforglipron), approved April 1, 2026, offering roughly 11–12% average weight loss at 72 weeks — needle-free and once daily. Injectable tirzepatide, a different (dual-agonist) molecule, still tends to produce greater average loss, around 15–21% by dose. Compounded tirzepatide remains not FDA-approved and now depends on patient-specific compounding with a documented clinical need. The right choice depends on your goals, tolerance for injections, cost, and health history — decide it with a licensed clinician rather than by default.
FAQ
Is there now a weight-loss pill instead of an injection? Yes. The FDA approved Foundayo (orforglipron), the first small-molecule GLP-1 pill for chronic weight management, on April 1, 2026. It is a once-daily tablet, unlike injectable tirzepatide.
Does the oral pill work as well as injectable tirzepatide? On average, no. In its ATTAIN-1 trial the highest dose produced roughly 11 to 12 percent average body-weight loss at 72 weeks, while injectable tirzepatide averaged about 15 to 21 percent by dose in SURMOUNT-1. The pill trades some efficacy for convenience and FDA approval.
Is Foundayo the same drug as tirzepatide? No. Foundayo (orforglipron) is a single GLP-1 receptor agonist and a non-peptide small molecule. Tirzepatide is a dual GIP and GLP-1 receptor agonist given by injection. They are different medicines.
Should I switch from compounded tirzepatide to the pill? That is a decision to make with a licensed clinician. The pill is FDA-approved and needle-free; injectable tirzepatide typically produces greater weight loss. Compounded tirzepatide is not FDA-approved. Compare results, cost, access, and your own health history.
Important: Compounded tirzepatide is not FDA-approved and is not the same medicine as Mounjaro or Zepbound, the only FDA-approved tirzepatide products (Eli Lilly and Company). This page is educational and is not medical or legal advice. Telehealth medications require evaluation and, when appropriate, a prescription from a licensed clinician. Regulatory status can change; confirm current FDA status, pricing, state availability, and pharmacy details directly before acting.